China’s Marine Biopharmaceutical Industry: Existing Problems and Countermeasures
2014-05-15ZHANGLijunHUANGTaikang
ZHANG Li-jun, HUANG Tai-kang,
(1. School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2. China Food and Drug Administration, Beijing 100810, China)
China’s Marine Biopharmaceutical Industry: Existing Problems and Countermeasures
ZHANG Li-jun1, HUANG Tai-kang1,2
(1. School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2. China Food and Drug Administration, Beijing 100810, China)
Objective To explore the problems faced by marine biopharmaceutical industry in China and to put forward countermeasures. Methods Literature review was conducted and the problems faced by China’s marine biopharmaceutical industry were analyzed from the perspectives of scale, technology, f i nancing, management and distribution. Accordingly, countermeasures were raised. Results and Conclusion Marine biopharmaceutical industry is the strategic emerging industry. The existing problems in the development of marine biopharmaceutical industry in china will be solved through strengthening overall coordination, promoting management innovation, consolidating science and technology, fostering industrial cluster and increasing capital investment.
marine biopharmaceutical industry; industrial development; problem analysis
Marine biopharmaceutical industry refers to the extraction of effective components from marine organisms. It is the activity of using biological technology to produce biochemical drugs, health products and genetically engineered drugs. China has abundant marine biological resources, which will provide a wealth of raw materials for the development of marine biopharmaceutical industry. In recent years, a great progress has been made in marine biopharmaceutical industry in China; in particular, the“Twelfth Five-year Plan” of the state passed the national marine economy development strategy, which brought marine biopharmaceutical industry bigger space to develop.
1 The development situation of marine biopharmaceutical industry in China
In recent years, the coastal cities have made great efforts to develop marine economy demonstration areas where marine biopharmaceutical industry was taken as one of the strategic emerging industries and became the focus in these cites. Four marine biotechnology and drug research centers were gradually formed in Shanghai, Qingdao, Xiamen and Guangzhou. Under the vigorous support of national policy, marine biopharmaceutical industry has obtained rapid development and presented a good trend. From 2006 to 2012, the total production of marine biopharmaceutical industry in China showed a rising trend year by year. In 2012, marine biopharmaceutical industry realized an output value of 58.9 billion Yuan compared with 2011, the added value was 17.2 billion Yuan, increased by 13.8%. The gross value of production of marine biopharmaceutical industry in China was shown in Figure 1.

Figure 1 The marine biopharmaceutical industry output value table in 2006-2012 in our country.
From Figure 1, the development of marine biological medicine resources had a major breakthrough, the output value of marine biopharmaceutical industry increased year by year. According to statistics, there were dozens of units and hundreds of marine biopharmaceutical industry carried out marine drug research, development, and production. Normal marine medicine production has reached nearly more than 30 varieties, compound Chinese traditionalmedicine nearly 2000 kinds. More than 10,000 kinds of new type of compounds were found from the marine organisms, of which more than 200 have been patented. After retrieving the State Food and Drug Administration data of 2012, we found that polysaccharide sulfate, sugar ester, nicotinic acid and other 6 kinds of new drugs and dozens of kinds of marine health products have been approved. 292 batch productions have been approved for the sodium alginate double ester products, including 25 active pharmaceutical ingredients, 215 tablets, and 52 injections. Marine medicine production scale is one of the largest listed varieties in China. 5 kinds of marine candidate drugs, such as new antitumor, resistance to heart and neurodegenerative disease are now in clinical research stage. In addition to the above five kinds of drugs, other marine drugs for kidney diseases are in the pre-clinical or clinical stage. Generic or secondary derivative marine medicines are more than 30 as well as dozens of special functional foods, such as konka, haili and so on. Now the development of marine drugs in the treatment of cancer, cardiovascular disease, AIDS, etc have showed great potential. At the same time, we can see from Figure 1 that the growth rate of output in marine biopharmaceutical industry f l uctuated a lot which means the development of marine drugs were greatly influenced by external factors, such as policy and economy.
2 China’s marine biopharmaceutical industry development issues
Through long-term accumulation, the development of marine biopharmaceutical industry in China has very good conditions, a solid foundation and favorable policy, but there are still some problems for marine biopharmaceutical industry, namely the following respects display them.
2.1 Small scale and low degree development
Marine biopharmaceutical industry started relatively late and its research time was shorter compared with other pharmaceutical industries, Therefore, it has a very small share in the whole pharmaceutical industry. We can take Qingdao as an example, it is the domestic and foreign famous marine science and technology city, and it has advantages in the marine biological medicine research and industrialization development. However, this advantage has not been converted into industry contribution. Marine biopharmaceutical industry in Qingdao, on the other hand, has not yet been converted into products. The output of whole pharmaceutical enterprises in Qingdao was only 9 billion yuan, the output was the same as one of the Shandong’s pharmaceutical companies, which total products ranked eighth in the whole province. Chemical pharmacy takes the lead and marine biological medicine has a very small proportion in the whole industry.
2.2 Technological backwardness and low capacity of independent innovation
Although China has rich marine biological resources, the development of marine biopharmaceutical industry need enzyme and receptor as a target of high-throughput screening to separate marine microbial metabolites. Based on proteomics, nuclear magnetic resonance (NMR), databases, and the tall secretors end recognition technology, we can fully disclose the rare compounds of biological mechanism from marine resources, and to encode marine biological genetic resources, such as regulation and expression techniques. In terms of technology, our country does not have high standard of technology platform and long-term competitiveness drugs research ability. At the same time, there are few scientific research centers which can participate in international competition and stand in the frontier of science and technology. We have few biopharmaceutical drugs with original innovation, but the follow-up types, generic drugs, repeated research and development is serious. In terms of talent, we lack of excellent management talents with forward-looking strategic vision At present, the people engaged in marine drug production, either do not have pharmacological knowledge, or don't understand the production technology which severely affect our pharmaceutical production quality. At the same time, the poor basic qualities and low learning ability hinder them to grasp operating technology and result in the low productivity. Backward technology and the lack of talent will seriously affect the enterprise independent innovation, thereby weakening the ability and speed of marine biopharmaceutical industry development.
2.3 Enterprise financing problem and insufficient investment
At present, the development of marine industry in China is at a crucial period towards the industrialization. Some experts pointed out we should increase investment in capital and technology to ensure its sustainable development. On the one hand, marine medicine production process is complex and it takes long time to research, test, and have the clinical research, which makes the marine biopharmaceutical enterprise face big risk of financing. So the investors who are not familiar with dynamics andthe characteristics of the investment will stop investing when they face the great uncertainty and risk. It is hard for enterprise to make the external f i nancing. On the other hand, due to the limitations of marine drugs, enterprise will have greater market risk and the phenomenon of instance success is very serious in this industry, which prevents the injection of additional funds.
2.4 Imperfect management standards and old system
Now the combination of government guidance and market function in our country are not in place, and the use of preferential policies and the operation of the market rule are not harmonious as well. There are also other problems such as most enterprises do not have the strategic plan, and they can not optimize the allocation of resources. The standardization management system in marine biopharmaceutical enterprise has not yet formed which means the enterprise management mechanism is not fl exible. These enterprises do not have specialized leading products and the quality of the products are low, too.
2.5 Scattered distribution of resources
In the rapid expansion of the development, marine biopharmaceutical industry also exposed the problem of scattered resources. In recent years, although China has formed a large number of industrial zones, most zones are full of enterprises with traditional textile, food, and mechanical processing, high and new technology industry is less. Special biological medicine and marine biological medicine industrial zones are much rarer. And even in marine biological medicine industrial zones, they do not have centralized layout and industrial chain with characteristics, but with low technical level, small scale project and low industry correlation degree etc.
3 The countermeasures to speed up the marine biopharmaceutical industry development in China
3.1 Strengthening overall coordination, creating a favorable environment for the development of marine biopharmaceutical industry
Marine biopharmaceutical industry has been positioned as our national strategic emerging industries, and as the government has promulgated the “Bio-industry Development Plan” and other specif i c plans. All provinces should follow the planning requirements strictly, and make their own plans according to the regional characteristics, and actual situation, so that the industry can develop healthily and scientifically. At the same time, we should create a favorable environment for marine biopharmaceutical industry by introducing beneficial policy, optimizing related facilities, and timely coordinating and solving the diff i culties and problems encountered in the development of the industry. The government should provide guidance and help for enterprises’ market access, product technology R & D, patents and standards so as to speed up the innovation and development, to open up new markets and improve enterprise competition ability.
3.2 Promoting the innovation of management system and strengthening the macro-control, to safeguard the development of marine biopharmaceutical industry
“Twelfth-Five-Year Plan” period is the key period for building an innovation oriented country. Enterprise independent innovation is comprehensive which includes the technological innovation as the support, the management innovation to enhance the management level and the system innovation to, improve the mechanism and system eff i ciency. Therefore, f i rst we should establish and perfect the management mechanism to promote marine biopharmaceutical industry, encouraging social resources to participate in the development of marine biopharmaceutical industry. Second, we should strengthen the cohesion of relevant planning and national science and technology projects so that we can guide for the major projects of marine biological medicine. Third, we should improve the management level of enterprises and actively promote their innovation. By strengthening the strategic planning, property rights, finance, investment and information management, enterprise management will gradually become intensive, information-based type.
3.3 Establishing an effective platform for the R&D and innovation by integrating scientific research strength
The combination of research and commercialization is an effective way for enterprises to carry out creative work. And the commercialization of research f i ndings is a complicated system, which is hard for personal or business alone. On the one hand, government should provide comprehensive support to the enterprise by encouraging innovation, market counseling and favorable taxation etc. For example, the government can announce a number of key technologies for project bidding to encourage enterprises,
scientif i c research institutions, colleges and universities to cooperate, then it will be easy to commercialize the research finding. At the same time, government should make good use of the public information resources to serve enterprises and talents. Government should guide enterprises to improve internal management by raising wages, improving the working environment to reduce the loss of talented people and attract various talents required. On the other hand, we should attach great importance to the cultivation of high level research and development technical staff for the development of China's marine biopharmaceutical industry. To attract domestic and foreign scientif i c and technological personnel widely and establish an effective platform, the enterprises can improve their research and development capabilities.
3.4 Establishing advantages, highlight the characteristics of industrial park, and cultivate innovative marine biopharmaceutical industry cluster
In recent years, many marine biopharmaceutical industry zone are being constructed in Shanghai, Shandong, Liaoning, Zhejiang, Fujian and other provinces and they are going to create national marine biological medicine industry bases. At the same time, they should pay attention to the regional characteristic and take the advantage of the development of marine biopharmaceutical industry. Taking Dafeng of Jiangsu as an example, Dafeng is the key coastal city for the new industry. Since 2011, Dafeng has focused on marine biopharmaceutical industry as the strategic emerging industry and made efforts to create billions of industrial clusters. Another example is Zhang Jiang of Shanghai marine biological medicine zone, in order to speed up the construction of Shanghai marine biopharmaceutical industry base, Zhang Jiang fully took advantages of many universities and institutes with good industrial infrastructures to focus on the development of marine biotechnology medicine, modern medicine biological reagents, fermentation engineering and other high-tech products. It also promoted the construction of marine biotechnology innovation and industrialization platform, optimizing the industrial layout and finally it became an inf l uential marine biomedical industry in China.
3.5 Increasing capital investment for the development of marine biopharmaceutical industry
The shortage of funds is one of the major factors that hinder the rapid development of marine biopharmaceutical industry in china. Therefore, the Financial Department and the Committee of Science should increase funding for marine drug R & D, state funds should also be invested into provinces with relatively developed marine drug research. First, we can establish special marine drug development fund. On the one hand, enterprises are given preferential policies in the loan and tax. On the other hand, enterprises should be encouraged to carry out technological transformation and innovation so that they can perform R & D as soon as possible. Second, enterprises can raise fund for research and development through multi-channels and government can increase credit f i nancing support. Based on credit classification management, government can support the enterprises by giving them different interest rates and other means, such as actively offering solutions to business problems, developing the network of mortgage loan and promoting the commercial bill etc. By strengthening the connection between the government, enterprises and banks, the leading enterprises can get loans from banks. Enterprises can also alleviate the f i nancing pressure with the help of a series of preferential policies on tax cut.
4 Conclusions
Marine biopharmaceutical industry, as a strategic emerging industry, will provide important support for the rapid and sound development of the national economy. Although there are still a lot of problems in the current development of China’s marine biopharmaceutical industry, with the time passing by, marine biopharmaceutical industry in China will have a good and fast development.
[1] GU Tuan-li, CHEN Hai-sheng, CAO Xiao-li. Problems of Enterprises’ Biological Pharmaceutical R&D Financing Channel Structure and Its Countermeasures [J]. Friends of Accounting (The Magazine), 2007, 05: 36-37.
[2] WEN Yan. Marine Drug Development Present Situation and Future Development Trend Analysis [J]. Chinese Fishery Economy, 2006, 03: 43-49.
[3] LIAN Gui-yu, HUANG Tai-kang. Development of Chinese Biopharmaceutical Industry’s Problems and Countermeasures [J]. China Pharmaceutical, 2006, 16: 16-17.
[4] LI Chun-xia, SUN Yang, HUA Shi. Marine Drug Development in Tube of Alginic Sodium Diester Research and Enlightenment of [J]. Life Science, 2012, 24(9): 1019-1024.
[5] LIU Kun. China Emerging Industries of Strategic Marine Cultivation Mechanism of [D]. Qingdao: Ocean University of China, 2013: 108-109.
Author’s information: ZHANG Li-jun. Major research area: Regional economic management. Tel: 0580-2281666, E-mail: max2088@sina. com
杂志排行
亚洲社会药学杂志的其它文章
- Patent Status of Antidepressants: Duloxetine
- Countermeasures to Reduce Economic Burden of the Schizophrenia in China
- Marketing Channel Selectionsfor Different Biological Reagent Enterprises in China
- Research of the Classif i cation of Drug Risks
- The Comparison of IND Review Mechanism between China and the United States
- Biosimilars: Current Status and Countermeasures
